Retatrutide is an investigational peptide compound that acts as a triple agonist, targeting three hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Without consistency across trials, it becomes difficult to draw firm conclusions or develop universal guidelines for use [45, 46]
In mitochondrial disease there is low inter-cellular ATP
Hepatocellular hypertrophy and hyperplasia often occur together in response to enzyme inducers, and the histologic diagnosis is often based on the relative predominance of the two
Contraindications You should not receive MIC+B12 injections if you: Have a known allergy or hypersensitivity to any of the ingredients or their preservatives
cag not Cagrilintide + Retatrutide Neither approved Feature Injections per week Cagrilintide + Tirzepatide 2 (separate vials) CagriSema (Cag + Sema) 1 or 2 Cagrilintide + Retatrutide 2 (separate) or 1 (pre-blend) Feature Estimated grey-market cost Cagrilintide + Tirzepatide $500-$1,000/month CagriSema (Cag + Sema) $500-$900/month Cagrilintide + Retatrutide $600-$1,200/month Cost ranges reflect typical research-grade pricing as of June 2026 - verify supplier pricing before ordering
